<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896489</url>
  </required_header>
  <id_info>
    <org_study_id>2000026404</org_study_id>
    <nct_id>NCT04896489</nct_id>
  </id_info>
  <brief_title>Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking</brief_title>
  <official_title>Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hydrocortisone biases formation of&#xD;
      alcohol-related memories to potentiate drinking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to 1) Characterize the effect of elevated glucocorticoids during encoding on&#xD;
      long-term memory for alcohol-related information; 2) Identify the neural mechanisms by which&#xD;
      glucocorticoids influence encoding of alcohol-related experiences; and 3) Determine how&#xD;
      glucocorticoid modulation of alcohol-related encoding relates to drinking after retrieving&#xD;
      alcohol-related memories.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes fMRI signal</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes in fMRI signal at encoding will be assessed over an hour long period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Item memory</measure>
    <time_frame>Up to 90 minutes</time_frame>
    <description>Item memory will be assessed through performance on delayed memory assessments. Item memory is determined by the accuracy of memory for individual items and will be expressed as dprime.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Context memory</measure>
    <time_frame>Up to 90 minutes</time_frame>
    <description>Context memory will be assessed through performance on delayed memory assessments. Context memory is determined by the accuracy of memory for associated contexts and will be expressed as % correct.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Affect memory</measure>
    <time_frame>Up to 90 minutes</time_frame>
    <description>Affect memory will be assessed through performance on delayed memory assessments. Affect memory is determined by subjective ratings of vividness (1-4), change in ratings from encoding to retrieval of memory (0-3). The score is averaged where a higher score indicates greater affect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol motivation</measure>
    <time_frame>10 minutes</time_frame>
    <description>Performance on alcohol taste test following memory retrieval will be assessed using the Alcohol Taste Test (ATT). The test asks participants to taste the alcohol in each two containers to identify whether the alcohol was the same or different. The % correct is used to assess this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affect - Negative</measure>
    <time_frame>10 minutes</time_frame>
    <description>Self-reported measures of emotional state following drug administration and memory retrieval using the PANAS. The negative subscale of the PANAS will be used and has a range of 10-50. Higher scores indicate higher negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affect - Positive</measure>
    <time_frame>10 minutes</time_frame>
    <description>Self-reported measures of emotional state following drug administration and memory retrieval using the PANAS. The negative subscale of the PANAS will be used and has a range of 10-50. Higher scores indicate higher positive affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrine/cortisol reactivity</measure>
    <time_frame>Baseline to 2 hours</time_frame>
    <description>Change in salivary cortisol levels following the hydrocortisone/placebo administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Alcohol Drinking</condition>
  <condition>Drinking Behavior</condition>
  <condition>Episodic Memory</condition>
  <condition>Long-term Memory</condition>
  <arm_group>
    <arm_group_label>hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive hydrocortisone (20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone 20 MG</intervention_name>
    <description>Participants receive Hydrocortisone 20 MG</description>
    <arm_group_label>hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read and write English&#xD;
&#xD;
          -  BMI 18-35&#xD;
&#xD;
          -  Beer drinking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meet current criteria for any substance use disorder, excluding caffeine&#xD;
&#xD;
          -  Current significant medical conditions or psychiatric symptoms requiring medication&#xD;
&#xD;
          -  Current use of medications/drugs that interfere with the HPA axis response&#xD;
&#xD;
          -  Peri and post-menopausal women, pregnant or lactating women, and those with&#xD;
             hysterectomies&#xD;
&#xD;
          -  Metal in body (for MRI safety)&#xD;
&#xD;
          -  Systemic fungal infections (contraindication for hydrocortisone)&#xD;
&#xD;
          -  Known hypersensitivity to components of hydrocortisone tablets (hydrocortisone,&#xD;
             calcium stearate, corn starch, lactose, mineral oil, sorbic acid, sucrose)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth V Goldfarb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth V Goldfarb, PhD</last_name>
    <phone>203-737-6365</phone>
    <email>elizabeth.goldfarb@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth V Goldfarb, PhD</last_name>
      <phone>203-737-6365</phone>
      <email>elizabeth.goldfarb@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth V Goldfarb, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Drinking Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in published articles will be shared after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Immediately following publication with no end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to have access to the data may do so.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

